Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

47 trials with published results (15%)

Research Maturity

185 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

24 terminated out of 312 trials

Success Rate

88.5%

+2.0% vs benchmark

Late-Stage Pipeline

12%

38 trials in Phase 3/4

Results Transparency

25%

47 of 185 completed with results

Key Signals

47 with results89% success24 terminated

Data Visualizations

Phase Distribution

179Total
Not Applicable (82)
Early P 1 (4)
P 1 (31)
P 2 (24)
P 3 (23)
P 4 (15)

Trial Status

Completed185
Unknown44
Recruiting28
Terminated24
Withdrawn15
Not Yet Recruiting8

Trial Success Rate

88.5%

Benchmark: 86.5%

Based on 185 completed trials

Clinical Trials (312)

Showing 20 of 20 trials
NCT07619547Not Yet RecruitingPrimary

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

NCT07532213RecruitingPrimary

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT05579392Not ApplicableRecruitingPrimary

A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

NCT07242248RecruitingPrimary

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

NCT07102368RecruitingPrimary

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

NCT00001184RecruitingPrimary

Immune Regulation in Ulcerative Colitis or Crohn s Disease

NCT07612267Phase 4Not Yet Recruiting

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT04751396Recruiting

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT02341742CompletedPrimary

Physical Activity and Bone Mineral Density in Children and Adolescents With Chronic Inflammatory Bowel Disease

NCT06483373Early Phase 1RecruitingPrimary

A Clinical Study of SPH7854 Granules in Healthy Subjects.

NCT02861053Not ApplicableTerminatedPrimary

Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?

NCT07143188Not ApplicableNot Yet RecruitingPrimary

The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares

NCT06346288Phase 4CompletedPrimary

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

NCT06623383CompletedPrimary

Correlation of Fecal Calprotectin and Fecal Immunochemical Test in Determination of Endoscopic Activity in Inflammatory Bowel Disease Patients

NCT02636517Phase 1Enrolling By Invitation

Fecal Microbiome Transplant

NCT07475052Enrolling By InvitationPrimary

Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD

NCT07466940Phase 1Active Not Recruiting

A Clinical Study to Evaluate SM17 in Healthy Participants

NCT07207200Not ApplicableRecruitingPrimary

Impact of Morning Light Therapy in IBD

NCT07210580Not ApplicableRecruitingPrimary

Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease

Scroll to load more

Research Network

Activity Timeline